智通财经APP获悉，随着今年并购交易活动强势启动，矿业巨头嘉能可在并购专家眼中成为2026年最有 可能被收购的欧洲企业。在媒体本月对30家风险套利交易台、交易员和分析师进行的一项非正式调查 中，正在与力拓(RIO.US)洽谈合并、以打造全球最大矿业公司的嘉能可被提及8次。 此外，调查结果显示，来自广泛行业的公司纷纷上榜，反映出随着全球经济动能增强，潜在收购方正将 目光投向更广阔的领域。法国生物科技公司Abivax SA被提及5次。该公司股价在2025年因潜在收购前景 以及积极的药物试验结果而暴涨逾1600%。英国石油(BP.US)、德国在线外卖订餐服务平台Delivery Hero SE、英国廉价航空公司EasyJet Plc和英国老牌房地产开发商Great Portland Estates则各被提及4次。 受访者还表示，全球并购环境正变得日益活跃。数据显示，今年以来截至1月23日，全球已宣布的并购 交易总额已超过630亿美元，是2025年同期记录金额的三倍以上。Neuberger Berman首席策略组负责人 约瑟夫·罗特表示："并购交易量尚处于回升的初期阶段。相比以往几年更偏向特定行业，如今的前景似 乎正 ...

Group 1: Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by over 200 points on Monday [1] Group 2: UniFirst Corporation - Shares of UniFirst Corp rose significantly after receiving an acquisition proposal from Cintas Corporation for $275 per share in cash [1] - The acquisition offer values UniFirst at approximately $5.2 billion, representing a 64% premium over its 90-day average closing price as of December 11, 2025 [1] - UniFirst shares surged by 21.8% to $207.50 during Monday's trading session [1] Group 3: Other Notable Stock Movements - Hycroft Mining Holding Corporation shares jumped by 48.3% to $24.35 following positive drill results from its exploration program [3] - Adeia Inc gained 28.6% to $16.43 after signing a long-term media IP license agreement with Disney and raising its 2025 outlook [3] - BlackSky Technology Inc saw a 17.9% increase to $22.70 after Jefferies initiated coverage with a Buy rating and a price target of $23 [3] - Cytokinetics, Inc. shares rose by 11.2% to $69.74 after FDA approval of MYQORZO for treating adults with symptomatic obstructive hypertrophic cardiomyopathy [3]

Group 1 - Deutsche Bank has regained a position in the Eurozone's Stoxx 50 index after being excluded for seven years, alongside Siemens Energy and Argenx SE [1] - The inclusion comes after Deutsche Bank's market value has more than doubled in the past 12 months, reflecting a rebound in European bank stocks [1] - Siemens Energy's stock has increased over twofold since September last year, benefiting from a surge in global electricity demand [1] Group 2 - The index company also announced adjustments to the broader Stoxx Europe 600 index, including the addition of French biotech company Abivax SA and Fraport AG, while removing Gerresheimer AG [2] - All changes to the index will take effect after the European market opens on September 22 [2]

Core Viewpoint - Abivax reported its full-year financial results for 2024, highlighting significant clinical progress and a strong cash position that supports its ongoing clinical trials and operational needs [2][3]. Financial Highlights - Total operating income for FY 2024 was EUR 12.5 million, an increase of EUR 7.9 million from EUR 4.6 million in FY 2023 [5]. - Research and Development (R&D) costs rose to EUR 146.5 million, up EUR 43.3 million from EUR 103.2 million in the previous year, primarily due to increased expenses related to the Phase 3 clinical trials for obefazimod [5][8]. - The net loss for the period was EUR 176.2 million, compared to EUR 147.8 million in FY 2023, reflecting higher operational expenditures [5][8]. - The cash balance as of December 31, 2024, was EUR 144.2 million, down from EUR 261.0 million in 2023, providing a cash runway into Q4 2025 [6][9]. Upcoming Milestones - Full enrollment in the Phase 3 ABTECT trial for obefazimod is expected in Q2 2025, with top-line results anticipated in Q3 2025 [6][7]. - Completion of the 44-week maintenance trial is projected for Q2 2026, with top-line results expected in the same quarter [7]. Operational Insights - The total number of employees increased to 69 as of December 31, 2024, from 61 in the previous year, indicating organizational growth [8]. - General and Administrative (G&A) expenses rose to EUR 32.9 million, up EUR 10.5 million from EUR 22.4 million in 2023, driven by increased headcount and legal fees associated with being a dual-listed company [8][12].